Chemical Knockout of Pantothenate Kinase Reveals the Metabolic and Genetic Program Responsible for Hepatic Coenzyme A Homeostasis  by Zhang, Yong-Mei et al.
Chemistry & Biology
ArticleChemical Knockout of Pantothenate Kinase
Reveals the Metabolic and Genetic Program
Responsible forHepaticCoenzymeAHomeostasis
Yong-Mei Zhang,1 Shigeru Chohnan,1,4 Kristopher G. Virga,2 Robert D. Stevens,3 Olga R. Ilkayeva,3
Brett R. Wenner,3 James R. Bain,3 Christopher B. Newgard,3 Richard E. Lee,2 Charles O. Rock,1
and Suzanne Jackowski1,*
1 Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA
2 Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA
3 Sarah W. Stedman Nutrition and Metabolism Center, Duke University Medical Center, Durham, NC 27704, USA
4 Present address: Department of Bioresource Science, College of Agriculture, Ibaraki University, Ibaraki 300-0393, Japan.
*Correspondence: suzanne.jackowski@stjude.org
DOI 10.1016/j.chembiol.2007.01.013SUMMARY
Coenzyme A (CoA) is the major acyl group car-
rier in intermediary metabolism. Hopantenate
(HoPan), a competitive inhibitor of the panto-
thenate kinases, was used to chemically antag-
onize CoA biosynthesis. HoPan dramatically
reduced liver CoA and mice developed severe
hypoglycemia. Insulin was reduced, glucagon
and corticosterone were elevated, and fasting
accelerated hypoglycemia. Metabolic profiling
revealed a large increase in acylcarnitines, illus-
trating the role of carnitine in buffering acyl
groups to maintain the nonesterified CoASH
level. HoPan triggered significant changes in
hepatic gene expression that substantially
increased the thioesterases, which liberate
CoASH from acyl-CoA, and increased pyruvate
dehydrogenase kinase 1, which prevents the
conversion of CoASH to acetyl-CoA. These
results identify the metabolic rearrangements
that maintain the CoASH pool which is critical
to mitochondrial functions, including gluconeo-
genesis, fatty acid oxidation, and the tricarbox-
ylic acid and urea cycles.
INTRODUCTION
Coenzyme A (CoA) is an essential cofactor that carries
carboxylic acid substrates and supports a multitude of
oxidative and synthetic metabolic reactions, including
those involved in the citric acid cycle, sterol biosynthesis,
amino acid metabolism, and fatty acid biosynthesis and
oxidation [1]. CoA is derived from vitamin B5 (pantothe-
nate), cysteine, and ATP. Pantothenate kinase (PanK) cat-
alyzes the first committed step and is the rate-controlling
enzyme in CoA biosynthesis [1–3]. PanK expression levels
define the upper threshold of the cellular CoA content
[4–6], and PanK biochemical activities are feedbackChemistry & Biology 14, 2regulated differentially by nonesterified CoA (CoASH) or
CoA thioesters [4, 6–10], providing a mechanism to co-
ordinate the rate of CoA synthesis with the demand for
the cofactor in metabolic pathways. Loss of the feedback
regulation by mutation at a single PanK residue results in
runaway CoA production [11].
The discovery of multiple PanK isoforms encoded by
four genes in humans [12–16] and mice [7] suggests
a complexity associated with diet-, drug-, and disease-
induced responses of the PanK activities which, in turn,
regulate CoA availability. Liver CoA levels are apparently
important in metabolic function, as hepatic total PanK ac-
tivity and CoA content are altered in response to nutritional
state [17–21], insulin [3], glucagon or glucocorticoids [18],
fibrate drugs [17, 22–25], and diabetes [26, 27]. The hu-
man PanK2 is a mitochondrial isoform [14, 28, 29] that is
sensitive to inhibition by submicromolar acetyl-CoA [16],
and mutations that inactivate this isoform are associated
with a neurodegenerative disorder [12, 14, 28, 29]. Loss
of one or more of the PanKs would presumably lead to
chronically reduced tissue CoA levels, but details about
the molecular sequelae that accompany such a disorder
are lacking. We investigated the biochemical and genetic
alterations imposed on animals by reduced CoA using
a pantothenate antimetabolite, hopantenate (HoPan; Fig-
ure 1A) to chemically ablate CoA biosynthesis. The data
show that nonesterified CoASH is the most important
component of the CoA pool that is necessary for mito-
chondrial function. The experiments also illustrate the
metabolic and genetic processes that realign in an effort
to maintain the level of CoASH. These data provide insight
into the molecular shifts that may contribute to a loss of
physiological function due to CoA deficiency.
RESULTS
Biochemistry of HoPan Action
HoPan is a structural analog of pantothenate containing
an extra methylene group (Figure 1A), and we identified
this molecule as a pantothenate kinase inhibitor as part
of an enzyme-based screen of pantothenamides and91–302, March 2007 ª2007 Elsevier Ltd All rights reserved 291
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CoASH and Mitochondrial FunctionFigure 1. HoPan Inhibition of Pantothe-
nate Kinase
(A) In HoPan (hopantenate), the b-alanine moi-
ety of pantothenic acid is substituted with g-
aminobutyric acid (GABA), a neurotransmitter,
that contains an additional methylene group.
(B) HoPan inhibited mouse PanK1a (d),
PanK1b (B), PanK2 (-), and PanK3 (,) with
IC50 values between 50 and 150 mM. The pro-
karyotic E. coli PanK (:) was refractory to Ho-
Pan inhibition. Data presented are means with
standard errors unless otherwise indicated.
(C and D) Kinetic analysis of the inhibition of
PanK1a by HoPan illustrated that HoPan inhi-
bition was competitive with pantothenate (C)
and noncompetitive with respect to ATP (D).
The mode of inhibition was determined at sev-
eral HoPan concentrations: 300 mM (-),
150 mM (,), 75 mM (d), and 0 mM (B).
(E) (R)-HoPan (d) inhibited mPanK1a, but
(S)-HoPan (B) was not active.
(F) PanK assays performed using [32P]ATP
showed that HoPan was phosphorylated by
mPanK1a as well as the authentic pantothe-
nate substrate. Products were detected by
thin-layer chromatography as described in
Experimental Procedures.related structures [30]. The PanK1a, PanK1b, PanK2, and
PanK3 proteins were expressed in 293T cells to evaluate
their sensitivities to HoPan (see Figure S1 in the Supple-
mental Data available with this article online). The putative
PanK4 was not enzymatically active when expressed in
HEK293T cells (Figure S1). HoPan inhibited all active
PanK isoforms with IC50s between 50 mM and 150 mM in
our in vitro assays (Figure 1B). Purified Escherichia coli
PanK (CoaA), the prototypical type I pantothenate kinase,
was refractory to inhibition (Figure 1B). HoPan inhibition of
all the mammalian PanKs was consistent with the high de-
gree of similarity among their catalytic domains [4, 6, 7, 12,
16]. Likewise, the PanK from Aspergillus nidulans, which
belongs to the same PanK family as the mammalian iso-
forms [31], was inhibited by HoPan [30].
Analysis of the steady-state kinetics of the PanK reac-
tion revealed competitive inhibition by HoPan with respect
to the natural pantothenate substrate, as illustrated with
PanK1a in Figure 1C. Lineweaver-Burk plots of 1/v versus292 Chemistry & Biology 14, 291–302, March 2007 ª2007 Else1/[ATP] demonstrated that HoPan was a noncompetitive
inhibitor with respect to ATP (Figure 1D). The mode of in-
hibition was the same for PanK1b (Figure S2). Inhibition of
PanK was stereoselective for the (R) isomer of HoPan
(Figure 1E). We tested the reactivity of the inhibitor HoPan
using [g-32P]ATP and PanK1a and detected phosphory-
lated HoPan formation (Figure 1F), revealing that HoPan
was a pantothenate antimetabolite.
Physiological Effects of HoPan
HoPan was not toxic to cultured HEK293T, HepG2, or
PC12 cells at concentrations up to 800 mM (Figure 2A).
These experiments were performed in pantothenate-free
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 1 mM pantothenate and dialyzed serum (up
to 800:1 ratio of inhibitor to substrate). Consistent with
its inhibitory effect on the PanKs in vitro, however, HoPan
inhibited pantothenate incorporation into CoA in isolated
primary hepatocytes, resulting in a blockade of CoAvier Ltd All rights reserved
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CoASH and Mitochondrial FunctionFigure 2. Toxicity of HoPan
(A) HoPan was not toxic to cultured cells.
HepG2 (d), HEK293T (B), and PC12 (:) cells
were treated with HoPan at the indicated con-
centrations (800 mM, 400 mM, 200 mM, and
100 mM). Viable cells excluding trypan blue
stain were counted after two doubling times.
The number of viable cells is presented as the
percentage of the control cells treated with
dimethyl sulfoxide (vehicle alone).
(B) HoPan inhibition of CoA synthesis in iso-
lated hepatocytes. Hepatocytes were isolated
from male mouse liver and incubated with
[3H]pantothenate in the presence (d) and ab-
sence (B) of 5 mM HoPan. Hepatocytes were
extracted and fractionated by thin-layer chro-
matography on silica gel H layers developed
in solvent I (butanol:acetic acid:water, 5:2:3,
v/v) and solvent II (ethanol:28% ammonium
hydroxide, 4:1, v/v) (inset). Pan, pantothenate;
b-Ala, b-alanine.
(C) HoPan was phosphorylated in vivo. Hepa-
tocytes were labeled with [3H]HoPan and the
HoPan-derived intermediates were separated
on thin-layer chromatography developed in
solvent I and solvent II (inset). P-HoPan, phos-
phorylated HoPan.
(D) Survival of C57BL/6 mice (male,-, n = 22,
p < 0.0001; female, d, n = 17, p < 0.0001)
treated with HoPan (100 mg/g/day) compared
to mice treated with an equal amount of HoPan
plus pantothenate (male,,, n = 9; female,B,
n = 9).
(E and F) CoA levels in HoPan-treated (hatched
bars) and control (open bars) mouse tissues. (E)
shows the distribution of CoA species in male
liver in control and HoPan-treated mice. HoPan
treatment significantly reduced the levels of
total CoA (p < 0.0001) and CoASH (p <
0.0001) in liver. (F) shows the CoASH levels in
four representative mouse tissues. There was
a significant drop of free CoA levels in liver
and kidney (p < 0.0001), but not in brain or heart
of HoPan-treated mice.
Error bars are standard errors of the mean.production (Figure 2B). Hepatocytes labeled with [3H]Ho-
Pan accumulated P-HoPan, demonstrating HoPan was
phosphorylated in vivo and was not metabolized by the
downstream enzymes of PanK (Figure 2C). The fact that
no [3H]Pan-derived intermediate accumulated in the
HoPan-treated cells indicated that PanK was the only
enzyme of CoA synthesis that was inhibited by HoPan
treatment. Nonetheless, we tested the effects of HoPan
and P-HoPan on the bifunctional CoA synthase in vitro.
The results showed that neither compound inhibited the
two activities of CoA synthase (data not shown). In con-
trast to immortalized cultured cells, animals rely heavily
on oxidative metabolism, gluconeogenesis is critical for
survival, and both processes depend on CoA. Thus, we
administered HoPan to male and female mice (100 mg/g/
day), all of which expired within 5 and 15 days, respec-
tively (Figure 2D). Control male and female mice given
HoPan plus an equal amount of pantothenate supplement
survived the 16 day course of the experiment, demon-Chemistry & Biology 14, 2strating that the end result of HoPan treatment was specif-
ically due to interference with pantothenate metabolism.
HoPan administration resulted in a precipitous de-
crease in liver total CoA levels, which were the highest
among the four tissues examined and dropped by 73%
(Figure 2E). Analysis of the distribution of CoA species
showed that CoASH (nonesterified CoA) was the most sig-
nificantly reduced in HoPan-treated liver. Kidney CoASH
levels were lower than liver, but also exhibited a significant
drop following HoPan (Figure 2F). Control male and female
livers (HoPan + pantothenate) had between 110 and
125 nmol/g wet weight of CoA, which were the same as
in mice maintained on chow without HoPan and regard-
less of pantothenate enrichment. The rapid CoA depletion
in male liver implied that hepatic CoA had a high turnover
rate compared to brain and heart. Assuming that CoA pro-
duction was completely inhibited following the first dose
of HoPan, the half-life for liver CoA was estimated to be
24–30 hr in male mice and90 hr in females. The different91–302, March 2007 ª2007 Elsevier Ltd All rights reserved 293
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CoASH and Mitochondrial Functionturnover rates of CoA could account for the sexual dimor-
phism we observed in the HoPan-treated mice. In addi-
tion, possible different pharmacokinetics (absorption,
excretion, and degradation of HoPan) in male and female
mice could also explain the sexual dimorphism.
The livers from HoPan-treated mice exhibited distinct
pathology characterized by marked vacuolization arising
from swollen mitochondria (Figure 3). The liver sections
stained with toluidine blue showed more lipid droplets,
shrunken nuclei, and pronounced vacuoles in the cyto-
plasm in the HoPan-treated mice (Figures 3A and 3B).
Transmission electron microscopy revealed that the
apparent vacuoles were swollen mitochondria (Figures
3C–3F). Also, the glycogen storage granules evident in
the control liver (Figure 3E) were missing from the
HoPan-treated liver (Figure 3F). The brain, kidney, and
heart exhibited normal histology in HoPan-treated male
mice (not shown), pointing to the liver as the most sensitive
target organ. All of the HoPan-treated animals also had
elevated serum triglycerides, indicating defective utiliza-
tion of this fuel source by the liver. Control sera from
mice treated with HoPan plus Pan had 93 ± 47 mg/dl
triglycerides, whereas sera from treated males had
230 ± 177 mg/dl (p < 0.05) (Table S1). The triglycerides
in mice treated with H2O vehicle was 76 ± 14 mg/dl (Table
S1), similar to the level of the mice supplemented with
pantothenate, demonstrating that pantothenate supple-
ment completely countered the effect of HoPan. Serum
triglycerides in female control mice increased from
55.3 ± 17.8 mg/dl in controls to 93.7 ± 78 mg/dl in
HoPan-treated animals (Table S1). This increase was not
statistically significant due to the variability in the data
from the treated females.
Mechanism of HoPan Toxicity
Mice that succumbed to HoPan had low to undetectable
(<20 mg/dl) glucose levels at or near the time they expired
(Figure 4A), implicating hypoglycemia as a primary cause
for death. A pyruvate tolerance test showed that the low
blood glucose in the experimental animals was due to
a defect in gluconeogenesis. Plasma glucose rose signif-
icantly in control animals following the injection of pyru-
vate; however, the HoPan-treated animals failed to con-
vert the pyruvate into glucose (Figure 4B). Treated mice
had lower levels of insulin (Figure 4C), and elevated levels
of glucagon (Figure 4D) and corticosterone (Figure 4E), in-
dicating a normal hormonal response to hypoglycemia
[32]. These data indicated a metabolic imbalance in liver
gluconeogenesis due to inadequate CoA rather than a hor-
monal deficiency. Also, HoPan moderately decreased lac-
tate levels in both male (8.3 ± 1.6 to 5.7 ± 2.4 mmol/ml)
and female (7.5 ± 3.8 to 5.3 ± 2.1 mmol/ml) mice (Table
S1), arguing against lactic acidosis as a cause of death.
We evaluated the response of female mice to fasting mid-
way through the 2 week HoPan treatment program to in-
vestigate their ability to switch to fatty acids as a fuel
source (Table S2). Animals treated with the antimetabolite
had serum glucose (254.7 ± 79.7 mg/dl; n = 15) similar
to controls (297.5 ± 52.8 ml/dl; n = 11), but were unable294 Chemistry & Biology 14, 291–302, March 2007 ª2007 Elseto maintain blood glucose during a 48 hr fast (61.1 ±
15.1 mg/dl; n = 31) and all 31 animals expired by 30 hr.
Alterations in Intermediary Metabolism
and Gene Expression
The carnitine and organic acid compositions of HoPan-
treated livers revealed several metabolic derangements
created by reduced CoA (Figures 4F and 4G). Total acyl-
carnitines increased significantly. All but one of the acyl-
carnitine species were either increased or remained the
same in HoPan-treated mice (Table S3) and the largest in-
creases were in the levels of acetyl- and proprionylcarni-
tine. Free carnitine was also elevated, but not nearly to
the same extent as the acylcarnitines (Table S3). Total or-
ganic acids did not appear to change in HoPan-treated
mice due to the dominance of this pool by pyruvate. How-
ever, the second most abundant acid, lactate, decreased
50%, consistent with decreased serum lactate levels in
HoPan-treated mice despite impaired gluconeogenesis.
The tricarboxylic acid (TCA) cycle intermediates succi-
nate, fumarate, and malate were all decreased (Figure 4G;
Table S3). In addition, urea cycle intermediates ornithine
and citrulline significantly accumulated in HoPan-treated
mice (Figure 4G).
Microarray analysis showed that more than 3500 probe
sets exhibited greater than 2-fold change with p < 0.05 in
the HoPan-treated livers compared to the controls. A mul-
tiple hypothesis testing was performed and the q value
was set at 0.05 to limit the false discovery rate to 5%
[33, 34]. This analysis yielded 939 probe sets. Replicate
probe sets representing the same genes were averaged
to generate 772 unique probe sets, of which 502 had
annotated biological processes indicating hepatic CoA
depletion had a major effect on gene expression. Gene
ontology analysis using the NetAffx Analysis Center [35]
was carried out to obtain a global view of the hepatic
genes affected by CoA depletion and correlate the signif-
icantly regulated probe sets with their biological functions.
The most significantly perturbed physiological processes
were lipid metabolism, organic acid/carboxylic acid me-
tabolism, and protein metabolism (Figure 5). Among lipid
metabolism genes, those responsible for biosynthesis
were significantly repressed, whereas the expression of
catabolic genes was elevated. For example, among the
most highly induced genes were the acyl-CoA thioes-
terases (between 13- and 45-fold), whereas fatty acid syn-
thase expression was reduced 5-fold (Table S4). Analysis
of the array data by sorting gene ontology based on the
subcellular location of the affected genes revealed that
the proteins altered in the processes shown in Figure 5
were mainly associated with two membrane-bound or-
ganelles, the endoplasmic reticulum and mitochondria.
This correlation arose from the association of many of
the lipid metabolism genes with the endoplasmic reticu-
lum, whereas the genes that affected organic acid metab-
olism are associated with the mitochondria.
A comparison between the gene expression array anal-
yses and metabolic profiling of the HoPan-treated mouse
livers revealed relationships between gene expressionvier Ltd All rights reserved
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CoASH and Mitochondrial FunctionFigure 3. Liver Pathology in HoPan-Treated Mice
Liver sections from a control male mouse (A) and a HoPan-treated mouse (B) stained with toluidine blue. Transmission electron microscopy at two
different magnifications of control male mouse liver (C and E) and HoPan-treated liver (D and F). L, lipid droplet; ER, endoplasmic reticulum;
M, mitochondria; P, peroxisome; N, nucleus; G, glycogen storage granules.Chemistry & Biology 14, 291–302, March 2007 ª2007 Elsevier Ltd All rights reserved 295
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CoASH and Mitochondrial FunctionFigure 4. Metabolic Imbalances in
HoPan-Treated Mice
(A) Plasma glucose levels of HoPan-treated
mice (female, d, n = 8, p < 0.0001; male, -,
n = 8, p < 0.0001) compared to mice treated
with an equal amount of HoPan plus pantothe-
nate (female,B, n = 9; male,,, n = 9). Lines
represent the means of each treatment group.
(B) Pyruvate tolerance test in mice (n = 5 per
group) treated with HoPan (d) or water (B).
Pyruvate injection significantly increased
blood glucose levels in control mice in 15 min
(p < 0.0001), whereas no significant increase
was observed in HoPan-treated mice.
(C–E) Serum insulin (C), glucagon (D), and cor-
ticosterone (E) levels in HoPan-treated male
mice. Closed symbols (d, -, A) designate
HoPan-treated mice and open symbols
(B, ,, >) designate the controls. The
changes of serum insulin (p = 0.014), glucagon
(p = 0.026), and corticosterone (p = 0.0013)
levels in HoPan-treated mice were statistically
significant.
(F and G) Alterations of liver acylcarnitines (F)
and organic acids (G) in HoPan-treated mice.
Asterisks indicate p < 0.05. A complete list of
the panel of acylcarnitines and organic acids
analyzed, their absolute tissue concentrations
in the control and treated mice, and the statis-
tical significance of the differences are found in
Table S3. Open bars are the controls and
hatched bars are the HoPan-treated mice.
Error bars are standard errors of the mean.(Table S4) and the perturbation in organic acid levels
(Figure 4G). The reduced levels of the TCA cycle interme-
diates succinate and fumarate correlated with a 2.9-fold
increase in expression of the downstream enzyme fuma-
rate hydratase (Fh1). The microarray data also provided
a basis for understanding the dysregulation of the urea
cycle, exemplified by increased ornithine and citrulline
intermediates following HoPan treatment. The expression
of ornithine carbamoyltransferase (Otc), which utilizes or-
nithine, was depressed 8.5-fold and the expression of
arginase (Arg2), which produces ornithine, increased
2.7-fold, consistent with the increased ornithine level
(Figure 4G). The higher level of citrulline was linked to
a 2.6-fold increase in the expression of the citrulline-
forming enzyme nitric oxide synthase (Nos3). PanK1 was
the only pantothenate kinase gene that was upregulated
(5.9-fold) in response to the blockade of CoA synthesis
by HoPan, and none of the enzymes downstream of
PanK in the CoA biosynthetic pathway was induced. Other
biological processes that were affected by reduced CoA
were the response to stress, development, and the im-
mune response. A complete list of the genes significantly
altered by HoPan treatment is presented in Table S4.296 Chemistry & Biology 14, 291–302, March 2007 ª2007 ElseDISCUSSION
The metabolomic and gene expression analysis identified
a program of adjustments focused on preserving the
CoASH concentration (Figure 6). CoASH is required for
several key mitochondrial reactions, including pyruvate
dehydrogenase, a-ketoglutarate dehydrogenase, and
fatty acid b-oxidation. The conversion of CoASH to ace-
tyl-CoA from glycolysis via pyruvate is reduced by the
136-fold upregulation of pyruvate dehydrogenase kinase
1, which phosphorylates and inactivates pyruvate dehy-
drogenase. Acyl-CoA thioesterases 1, 2, and 3 are signif-
icantly upregulated (13- to 45-fold), illustrating a genetic
adjustment to convert acyl-CoA to CoASH. Our metabolic
profiling results provide experimental verification for the
proposed role of carnitine as a sink to offload acyl moieties
from acyl-CoA, thereby liberating CoASH to support cy-
cling within mitochondria [36, 37]. The significant accumu-
lation of acylcarnitines (5.1-fold) and the upregulation of
carnitine palmitoyltransferase (4.7-fold) and carnitine ace-
tyltransferase (2.7-fold) following HoPan administration
are consistent with the function of carnitine in accepting
acyl groups from acylated CoA and releasing CoASH tovier Ltd All rights reserved
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CoASH and Mitochondrial FunctionFigure 5. Gene Expression Alterations in HoPan-Treated Mice
The biological processes that correlated with the most significant changes in gene expression by HoPan treatment. Probe sets (772) that showed
greater than 2-fold regulation, p < 0.05, and false discovery rate q < 0.05 were used in the gene ontology analysis. The graph was obtained using
the NetAffx Analysis Center. Each box (node) represented one annotated biological process. The probe set count threshold for each node was
set at 30. The color of the node was based on Chi square values: red indicates the most significant change, blue the least. A complete list of genes
significantly regulated by HoPan treatment is presented in Table S4.support gluconeogenesis and the urea cycle. The inability
of HoPan-treated mice to produce glucose from liver and
kidney is reflected by their inability to survive a brief fast
and their failure in a pyruvate tolerance test. The impair-
ment of gluconeogenesis and the accumulation of acyl-
carnitines in HoPan-treated mice are reminiscent of the
phenotype of mouse models of fatty acid b-oxidation dis-
orders. Acylcarnitines are formed within the mitochondria
and released into the cytosol. Unlike CoA thioesters, acyl-
carnitines pass through biological membranes and are
excreted in the urine, a diagnostic parameter for a number
of inborn errors in mitochondrial function [38–40]. How-
ever, the HoPan phenotype differs in that animals with
acyl-CoA dehydrogenase deficiencies accumulate serum
lactate [38].
Our data show that liver actively controls the intracellu-
lar CoA concentration through a balance of synthesis and
degradation. The synthetic arm of this regulatory cycle isChemistry & Biology 14, 29governed by the four isoforms of pantothenate kinase,
which are all expressed in liver. Each of these isoforms
has a distinctive sensitivity to feedback inhibition by di-
verse CoA species [6, 7, 16], enabling the CoA biosyn-
thetic flux to rapidly respond to branches of intermediary
metabolism that differentially impact components of the
CoA pool. Less is known about the genetic regulation of
PanK expression, but the upregulation of hepatic PanK1a
expression by fibrates [13] is an example of the modula-
tion of gene expression levels by nutritional regulators.
Adjustment of hepatic CoA levels in response to fasting
or feeding conditions, diet, disease, or treatment with
hypolipidemic drugs supports the importance of adjusting
CoA levels in the metabolic adaptation of liver to different
fuel sources [3, 10, 17–27]. Rapid turnover is a key feature
of important metabolic regulatory cycles, and the abrupt
cessation of CoA synthesis by HoPan leads to a precipi-
tous decline in hepatic CoA levels as the degradative1–302, March 2007 ª2007 Elsevier Ltd All rights reserved 297
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CoASH and Mitochondrial Functionbranch of the regulatory cycle continues. Nudt7 is a perox-
isomal protein that hydrolyzes CoASH and its thioesters
[41]. Nudt7 is highly expressed in liver and kidney, in con-
trast to brain and heart [42], and this expression pattern
correlates with liver and kidney exhibiting the most rapid
decline in the total CoA pool in HoPan-treated animals,
with the heart and brain being relatively unaffected (Fig-
ure 2F). Subcellular fractionation of mouse kidney showed
that virtually all of the CoA hydrolase activity was associ-
ated with the peroxisomes, pointing to Nudt7 as the pre-
dominant enzyme responsible for CoA turnover [42]. The
sexual dimorphism in the maintenance of hepatic CoA
levels noted in this study may be due to differential expres-
sion of the pantothenate kinase isoforms in males and
females, differences in the rates of CoA degradation, dif-
ferent pharmacokinetics toward HoPan, or a combination
of these processes.
SIGNIFICANCE
CoA is a key cofactor in intermediary metabolism and
its tissue levels are tightly regulated by the rate of
biosynthesis at the pantothenate kinase step. This
work integrates chemical genetics, metabolomics,
and genomics to provide a comprehensive view of
the abnormalities that arise from a defect in pantothe-
nate kinase. Regulation of the CoASH pool is critical
to support mitochondrial functions including gluco-
neogenesis, fatty acid oxidation, and the urea cycle.
Multiple biochemical and genetic mechanisms are
engaged tomaintain CoASH. The carnitine transacyla-
Figure 6. Mechanisms Buffering the Level of CoASH in Liver
Depletion of total hepatic CoA leads to a series of events that com-
bine to spare the CoASH pool. The fall in acetyl-CoA leads to a de-
crease in mitochondrial energy generation via the TCA cycle reflected
by the decrease in the concentration of 4-carbon organic acids par-
ticipating in the cycle. CoASH conversion to acetyl-CoA is blocked
both by the transfer of acetyl groups into the acetylcarnitine pool
and the induction of pyruvate dehydrogenase kinase (PDHK) that
phosphorylates and inactivates pyruvate dehydrogenase (PDH) shut-
ting off glucose entry into the TCA cycle. Long-chain acyl-CoAs are
removed by the elevated expression of thioesterases and carnitine
palmitoyltransferase (CPT) that shuttles acyl moieties to the acylcar-
nitine pool.298 Chemistry & Biology 14, 291–302, March 2007 ª2007 Elsetion systems play an important role in supporting
CoASH levels by offloading acyl groups from acyl-
CoAs. The alterations in intermediary metabolism in
HoPan-treated animals serve as amodel for themilder
disruption of CoA homeostasis that underlies the ab-
normalities in pantothenate kinase-associated neuro-
degeneration (PKAN), a hereditary disorder arising
from a deficiency in the mitochondrial PanK2 isozyme
[12, 14].
These results also provide insight into understand-
ing the toxicity of HoPan in humans. HoPan was orig-
inally developed as an antipsychotic drug to deliver
the neurotransmitter g-amino-iso-butyric acid to pa-
tients. HoPan showed some efficacy [43]; however,
the side effects were so severe that therapy was dis-
continued. The adverse side effects induced hypogly-
cemia, hepatic steatosis, and organic acid excretion
[44–48]. We attribute these side effects to the interfer-
ence of HoPan with hepatic CoA metabolism, and our
findings suggest that pantothenate supplementation
would overcome these side effects, as it does in our
mouse model.
EXPERIMENTAL PROCEDURES
Preparation of Pantothenate Kinases
Mouse PanK1a and PanK1b expression vectors were described previ-
ously along with the procedure for transfecting and assaying cell ly-
sates [7]. The mouse cDNAs homologous to the human PanK2 and
PanK3 proteins [12] were cloned into pcDNA3.1() (Invitrogen) and
the human cDNA encoding PanK4 [12] was cloned with an amino-
terminal His tag into pcDNA3.1/HisA (Invitrogen). Protein concentra-
tions were determined by the method of Bradford [49] using g-globulin
as a standard. A peptide SKDNYKRVTGTSLGC was synthesized and
coupled to keyhole limpet hemocyanin by the Hartwell Center for Bio-
technology, St. Jude Children’s Research Hospital, and was sent to
Rockland, Inc. (Gilbertsville, PA) for raising rabbit polyclonal antiserum
against PanK1, PanK2, and PanK3. Affinity-purified polyclonal anti-
body [7, 50] was used at a dilution of 1:500 (stock is 1.4 mg/ml) to
detect proteins by western blot. The His-tagged human PanK4 protein
was detected with anti-His rabbit IgG (Santa Cruz Biotechnology) used
as the primary antibody at a dilution of 1:500 (stock is 0.2 mg/ml).
Western blotting was used to confirm the expression of the PanK
isoforms in the cell lysate as described [6].
Synthesis of HoPan
In two separate reaction vials, 4-aminobutyric acid (340 mg, 3.3 mmol)
and diethylamine (345 ml, 3.3 mmol) were dissolved in methanol (10 ml).
Then to the first reaction vial (R)-pantolactone (390 mg, 3 mmol) was
added and to the second vial (S)-pantolactone (390 mg, 3 mmol)
was added. The reactions were stirred overnight at 60C, evaporated
to dryness, and dissolved in 20 ml of water. Each mixture was passed
through an Amberlite IR-120 (H+) ion-exchange column (2 cm3 10 cm)
and eluted with water until neutrality was obtained. These solutions
were then washed three times with dichloromethane to remove any ex-
cess pantolactone. The extracted solutions were then evaporated to
dryness to yield the (R)-4-(2,4-dihydroxy-3,3-dimethylbutylamido)bu-
tyric acid (1) and (S)-4-(2,4-dihydroxy-3,3-dimethylbutylamido)butyric
acid (2) products, respectively, as oily residues which crystallized
upon cooling. The Ca2+ salts of each product were obtained by dis-
solving each in 5 ml of methanol with the addition of 0.6 eq. of calcium
hydroxide according to the protocol of Kopelevich et al. [51]. The solu-
tions were gently warmed to 40C and filtered to remove anyvier Ltd All rights reserved
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yield each product as a white amorphous powder.
Calcium (R)-4-(2,4-dihydroxy-3,3-dimethylbutylamido)butyrate (1)
406 mg (53% yield), a white powder; 1H NMR (500 MHz, D2O) d 3.84
(s, 1H), 3.37 (d, J = 11.2 Hz, 1H), 3.25 (d, J = 11.2 Hz, 1H), 3.09 (t,
J = 6.8 Hz, 2H), 2.07 (t, J = 7.8 Hz, 2H), 1.63 (qin, J = 7.3 Hz, 2H),
0.79 (s, 3H), 0.76 (s, 3H); MS (ESI) 231.9 (M  1).
Calcium (S)-4-(2,4-dihydroxy-3,3-dimethylbutylamido)butyrate (2)
389 mg (51% yield), a white powder; 1H NMR (500 MHz, CH3OD)
d 3.95 (s, 1H), 3.49 (d, J = 11.0 Hz, 1H), 3.43 (d, J = 11.0 Hz, 1H),
3.28 (t, J = 6.8 Hz, 2H), 2.26 (t, J = 7.1 Hz, 2H), 1.82 (qin, J = 6.8 Hz,
2H), 0.97 (s, 3H), 0.95 (s, 3H); MS (ESI) 231.8 (M  1).
Synthesis of [3H]HoPan
To 4-amino-n-[2,3-3H]butyric acid (1 mCi, 96.0 Ci/mmol) in 2% ethanol
aq. (1 ml) was added cold 4-amino-butyric acid (1 mg, 10 mmol) in
methanol (100 ml) and the mixture was concentrated to dryness
in vacuo using a speedvac. The residue was resuspended in a solution
of diethylamine (1.3 ml, 13 mmol) in methanol (100 ml) and to which was
added (R)-pantolactone (1.7 mg, 13 mmol) in methanol (130 ml). The re-
action mixture was heated overnight at 60C and then concentrated to
dryness. The resulting residue was resuspended in water (200 ml) and
extracted with dichloromethane (200 ml) to remove any unreacted pan-
tolactone. The aqueous phase was passed through a minicolumn of
freshly activated Amberlite IR-120 (H+) ion-exchange resin and the
eluent was concentrated to dryness to afford [3H]HoPan (4-(2,4-
dihydroxy-3,3-dimethylbutylamido)-[2,3-3H]butyric acid).
Pantothenate Kinase Assays
The standard pantothenate kinase assays were performed as de-
scribed [7, 11]. HoPan phosphorylation was determined in a similar re-
action mixture containing pantothenate (90 mM) or HoPan (400 mM),
[g-32P]ATP (0.25 mM; specific activity 1 Ci/mmol; Amersham), MgCl2
(10 mM), Tris-HCl (0.1 M, pH 7.5), and 40 mg of protein from a soluble
PanK cell extract for a total volume of 40 ml. A 10 ml aliquot of the reac-
tion mixture was spotted onto an activated silica gel H plate (Analtech)
which was developed in butanol:acetic acid:H2O (5:2:4, v/v/v), and the
product was quantitated using ImageQuant (Molecular Dynamics).
HoPan Toxicity in Cell Cultures and Hepatocyte Labeling
HepG2 (American Type Culture Collection; ATCC), PC12 (ATCC), or
HEK293T cells were cultured in pantothenate-free DMEM supple-
mented with 1 mM pantothenate and 10% dialyzed fetal bovine serum
in the presence of various concentrations of HoPan. After two doubling
times (48 hr for HepG2 cells, 30 hr for HEK293T cells, and 192 hr for
PC12 cells), viable cells were counted, which excluded trypan blue.
Whole livers of two 4-month-old C57BL/6 male mice were harvested
and rinsed in ice-cold buffer A (each liter contained 3.9 g of NaCl, 0.5 g
of KCl, 24 g of HEPES, and 2.7 g of glucose; the pH was adjusted to
7.6). The liver was chopped with a Vibrotome tissue chopper at a set-
ting of 0.5 mm and resuspended in 20 ml of erythrocyte buffer (15 ml of
buffer A plus 5 ml of erythrocyte lysis buffer; Qiagen) in a 125 ml Erlen-
meyer flask, gently mixed, and allowed to settle. The supernatant was
carefully discarded, and the procedure with the erythrocyte buffer was
repeated twice. The tissue pieces were then resuspended in 30 ml of
digestion buffer (buffer A plus 0.7 g/l CaCl2, 0.5 mg/ml type I collage-
nase, and 6 mg/ml deoxyribonuclease) and incubated in a water bath
shaker at 37C at 120 rpm for 20 min. The tissue pieces were allowed
to settle on ice and the supernatant was transferred to a centrifuge
tube. The tissue pieces were resuspended in another 30 ml of diges-
tion buffer, the procedures were repeated twice, and the three super-
natants were combined. Cell suspension from the supernatants was
filtered through Spectra/Mesh nylon (41 mm; Fisher Scientific), and liver
cells in the filtrate were centrifuged down at room temperature at
100 3 g for 2 min. The cell pellet was resuspended in wash buffer
(each liter contained 8 g of NaCl, 0.35 g of KCl, 0.16 g of MgSO4,
0.18 g of CaCl2, 2.4 g of HEPES, and 15 g of BSA; the pH was adjustedChemistry & Biology 14, 291to 7.4) containing 10% erythrocyte lysis buffer (v/v) and centrifuged
down three times.
Mouse liver cells were resuspended in PBS containing 0.5% BSA to
the density of about 1 3 107 cells/ml. For each labeling experiment,
75 ml of the cell suspension was used. The cells were labeled with
2 mM [3H]pantothenate (50 Ci/mmol) in the presence of 5 mM hopanten-
ate or PBS (for control). For labeling with [3H]HoPan (90 mCi/mmol,
400 mM), 500 ml of the cell suspension was used. After a 6 hr incubation
at 37C, cells were harvested and washed twice with PBS. The cells
were lysed by sonication in 50 ml of lysis buffer (20 mM Tris-HCl [pH
7.5], 2 mM DTT, 5 mM EDTA, and 50 mM NaF). The identity of the in-
tracellular metabolites was determined by fractionating the cell lysates
by thin-layer chromatography on silica gel H plates developed in either
solvent I (butanol:acetic acid:water, 5:2:3, v/v) or solvent II (etha-
nol:28% ammonium hydroxide, 4:1, v/v) using the standards de-
scribed previously [2]. Sections (0.5 cm) were scraped from the plate
and the radioactivity was quantitated in 3 ml of scintillation fluid using
a liquid scintillation counter.
Animal Experiments
C57BL/6 mice (6 weeks old) were purchased from the Jackson Labo-
ratory and fed on a diet without pantothenate supplement (TD 95248;
Harlan) for 2 weeks prior to and during experimentation. Mice were
maintained at a room temperature of 72 ± 2F, room humidity of
50% ± 10%, and a 12 hr light, 12 hr dark cycle, with the dark cycle
starting at 1800 hr. For time-to-death assays, calcium (R)-HoPan
was dissolved in water and administered to 8-week-old mice daily
by stomach gavage. Control mice were given water or HoPan plus
an equal amount of pantothenate. In the fasting experiment, after
8-week-old female mice were administered HoPan at 100 mg/g/day
by gavage for a week, one group of mice was fasted while the other
group was fed as usual. HoPan was administered daily to both groups
during the fasting period. Water was supplied ad libitum. Blood was
drawn either by retro-orbital bleed or by cardiac puncture for glucose,
lactate, and triglyceride tests performed by the Diagnostic Lab of the
Animal Research Center, St. Jude Children’s Research Hospital.
Serum samples from HoPan-treated and control mice were sent to
Ani Lytics, Inc. for insulin and glucagon measurements. Serum cortico-
sterone levels were determined using the corticosterone enzyme im-
munoassay kit according to the manufacturer’s instructions (Cayman
Chemical). All procedures were performed according to St. Jude Chil-
dren’s Research Hospital Institutional Animal Care and Use Commit-
tee-approved protocols.
Pyruvate Tolerance Test
Female C57BL/6 mice (6 weeks old) were fed a low-pantothenate diet
(TD 95248; Harlan) for 2 weeks prior to and during experimentation.
Calcium (R)-HoPan (100 mg/g/day) or water was administered to the
mice by stomach gavage. After 1 week of treatment, the pyruvate
tolerance test was performed. The mice (five per group) were fasted
for 14 hr before receiving an intraperitoneal dose of pyruvate (in saline)
at 2 g/kg body weight. Plasma glucose levels were measured from the
tail blood using a FreeStyle blood glucose monitoring system (Thera-
Sense) at 0, 15, 30, 45, 60, 90, and 180 min after pyruvate infusion.
Measurement of CoA Species in Mouse Tissues
Extraction of different CoA species from mouse tissues and CoA as-
says were performed as described with modifications [52, 53]. Briefly,
mouse tissue (0.1 g) was homogenized in 0.4 ml of chilled 6%
perchloric acid containing 28 mM DTT. The precipitate containing
the acid-insoluble long-chain acyl-CoAs, such as palmitoyl-CoA,
was removed by centrifugation (1500 3 g, 4C, 10 min) and saved
for long-chain acyl-CoA determination. Free CoA and short-chain
acyl-CoAs, such as acetyl-CoA and malonyl-CoA, were acid soluble.
The supernatant was split into two tubes, one for free CoA measure-
ment, the other for both free and short-chain acyl-CoAs. For free
CoA extraction, 0.1 volume of 1 M Tris and 0.3 volume of 2 M KOH
were added before the pH was adjusted to 6.58.5 with 0.6 N HCl–302, March 2007 ª2007 Elsevier Ltd All rights reserved 299
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g, 4C, 10 min) and the supernatant was saved for CoA determination.
To extract free CoA and short-chain acyl-CoA from the other half of the
supernatant, 1 M KOH was used to adjust the pH to 1112. The mix-
ture was incubated at room temperature for 1 hr, neutralized with 0.6 N
HCl to pH 6.58.5, and centrifuged (15003 g, 4C, 10 min). The resul-
tant supernatant was extracted with an equal volume of hexane three
times before being used in the CoA determination assay. Long-chain
acyl-CoAs were extracted from the initial perchloric acid precipitated
pellet, which was washed with 0.6% perchloric acid containing 5
mM DTT and then washed with 5 mM DTT. The washed pellet was re-
suspended in 300 ml of 5 mM DTT and the pH was adjusted to 1112
with 1 M KOH. The mixture was incubated at room temperature
for 1 hr, neutralized with 0.6 N HCl to pH 6.58.5, and centrifuged
(1500 3 g, 4C, 10 min). The resultant supernatant was extracted with
an equal volume of hexane three times before being used in the CoA
determination assay. The reaction mixture for the CoA measurement
contained 200 mM Tris-HCl (pH 7.5), 8 mM MgCl2, 0.1% Triton X-
100, 2 mM EDTA, 20 mM NaF, 2.5 mM ATP, 10 mM [1-14C]lauric
acid, 100 ng of E. coli acyl-CoA synthetase (FadD), and tissue extract
(5–20 ml) containing 25–400 pmol of CoA, in a total volume of 100 ml.
The reaction was initiated by the addition of FadD, and the reaction
mixture was incubated at 35C for 30 min, followed by the addition
of 325 ml of methanol:chloroform:n-heptane (1.41:1.25:1, v/v/v) and
25 ml of 0.4 M acetic acid. After the mixture was mixed vigorously
and centrifuged, [1-14C]lauroyl-CoA in the upper phase was quanti-
tated by counting in 3 ml of ScintiSafe 30% using a Beckman LS
6500 scintillation counter. A standard curve using commercial CoA
was used to calculate the amount of CoA species in mouse tissue
extracts.
Metabolomic Profiling
Specimens of powdered liver tissue were homogenized in deionized
water, and tissue extracts were prepared as previously described
[54, 55]. Measurement of acylcarnitines, organic acids, and amino
acids in tissue extracts was done by direct-injection electrospray tan-
dem mass spectrometry, using a Quattro Micro LC-MS system
(Waters-Micromass) equipped with a model HTS-PAL autosampler
(Leap Technologies), a model 1100 HPLC solvent delivery system
(Agilent Technologies), and a data system running MassLynx software.
Transcriptional Profiling
Total RNA was isolated using TRIzol (Invitrogen) according to the man-
ufacturer’s instructions. Pelleted RNA was resuspended in nuclease-
free water and digested with DNase I to remove contaminating geno-
mic DNA. The integrity of the total RNA was determined using the
Agilent bioanalyzer Lab-on-a-Chip, and the RNA sample was con-
verted to cDNA, labeled, and fragmented using procedures recom-
mended by Affymetrix. Fragmented labeled cDNA (4.0 mg) was hybrid-
ized for 16 hr at 50C to GeneChip mouse genome 430 2.0 arrays
(Affymetrix). After washing, staining, and scanning of the arrays were
performed according to the manufacturer’s protocol (Affymetrix), the
arrays were analyzed using GeneChip Operating Software (GCOS)
and global scaling was used to normalize the data from different
arrays. Spotfire DecisionSite 8.2.1 and the NetAffx Analysis Center
[35] were used to analyze array results. The statistical analyses were
from six data sets (three control and three HoPan-treated livers) that
were independently processed and hybridized.
Statistical Analyses
The significance of HoPan treatment was determined using two-tailed,
unpaired t tests with the confidence intervals set at 95%. Data with
p values less than 0.05 are indicated with an asterisk in the figures.
Supplemental Data
Supplemental Data contain four tables and two figures and can be
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